Inhibition of MG132-induced mitochondrial dysfunction and cell death in PC12 cells by 3-morpholinosydnonimine

Chung Soo Lee1, Eun Sook Han, Eon Sob Park

  • 1Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul 156-756, South Korea. leecs@cau.ac.kr

Brain Research
|February 24, 2005
PubMed

Insights

3-morpholinosydnonimine (SIN-1) protects PC12 cells from proteasome inhibitor MG132-induced damage. SIN-1

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Proteasome inhibitors like MG132 induce cellular damage.
  • Mitochondrial dysfunction and oxidative stress are key mechanisms in MG132 cytotoxicity.
  • PC12 cells are a neuronal model used to study cell death pathways.

Purpose of the Study:

  • To investigate the protective effects of 3-morpholinosydnonimine (SIN-1) against MG132-induced cytotoxicity in differentiated PC12 cells.
  • To elucidate the role of nitric oxide (NO) and superoxide in mediating these protective effects.
  • To determine the impact of SIN-1 on mitochondrial membrane permeability and oxidative stress markers.

Main Methods:

  • PC12 cells were treated with MG132 and varying concentrations of SIN-1.
  • Mitochondrial membrane potential, reactive oxygen species (ROS) formation, and glutathione (GSH) levels were measured.
  • Inhibitory effects of SIN-1 were assessed using scavengers like Carboxy-PTIO and superoxide dismutase.

Main Results:

  • MG132 induced nuclear damage, mitochondrial dysfunction, ROS production, and GSH depletion.
  • SIN-1 significantly reduced MG132-induced cell death and GSH depletion in a dose-dependent manner.
  • SIN-1's protective effects were abolished by superoxide and NO scavengers, implicating these molecules in the mechanism.

Conclusions:

  • Nitric oxide and superoxide released from SIN-1 protect PC12 cells from MG132 cytotoxicity.
  • SIN-1 mitigates MG132-induced cell death by preserving mitochondrial membrane permeability and reducing oxidative damage.
  • These findings highlight a potential therapeutic strategy involving NO donors against proteasome inhibitor-induced neurotoxicity.

Related Concept Videos